Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Burgues, Juan Bergua
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022 Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022 Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL Sep 2021 - Dec 2021 : Submission for r/r DLBCL	Active, not recruiting	3	440	Europe, Canada, Japan, US, RoW	Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin	ADC Therapeutics S.A., ADC Therapeutics SA	Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma	06/25	06/28
EPCORE DLBCL-3, NCT05660967 / 2021-005744-29: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma	Recruiting	2	180	Europe, Japan, US, RoW	Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®	Genmab, AbbVie	Diffuse Large B-Cell Lymphoma	01/26	07/27
KB-LANRA- 1001, NCT05028751 / 2022-001279-15: A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)	Terminated	1/2	24	Europe, US	Lanraplenib, LANRA, Gilteritinib, XOSPATA®	Kronos Bio, Kronos Bio, Inc.	Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia	04/24	04/24
DSP-5336-101, NCT04988555: A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation	Recruiting	1/2	362	Europe, Canada, Japan, US, RoW	Enzomenib, azoles, Venetoclax, Gilteritinib, Azacitidine (AZA)	Sumitomo Pharma America, Inc.	Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute	04/27	10/27
BYON4413.001, NCT06359002: Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.	Recruiting	1	100	Europe	BYON4413	Byondis B.V.	Relapsed / Refractory AML, Relapsed / Refractory MDS	12/26	03/27

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Burgues, Juan Bergua
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022 Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022 Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL Sep 2021 - Dec 2021 : Submission for r/r DLBCL	Active, not recruiting	3	440	Europe, Canada, Japan, US, RoW	Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin	ADC Therapeutics S.A., ADC Therapeutics SA	Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma	06/25	06/28
EPCORE DLBCL-3, NCT05660967 / 2021-005744-29: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma	Recruiting	2	180	Europe, Japan, US, RoW	Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®	Genmab, AbbVie	Diffuse Large B-Cell Lymphoma	01/26	07/27
KB-LANRA- 1001, NCT05028751 / 2022-001279-15: A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)	Terminated	1/2	24	Europe, US	Lanraplenib, LANRA, Gilteritinib, XOSPATA®	Kronos Bio, Kronos Bio, Inc.	Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia	04/24	04/24
DSP-5336-101, NCT04988555: A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation	Recruiting	1/2	362	Europe, Canada, Japan, US, RoW	Enzomenib, azoles, Venetoclax, Gilteritinib, Azacitidine (AZA)	Sumitomo Pharma America, Inc.	Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute	04/27	10/27
BYON4413.001, NCT06359002: Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.	Recruiting	1	100	Europe	BYON4413	Byondis B.V.	Relapsed / Refractory AML, Relapsed / Refractory MDS	12/26	03/27